Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Immediately following tooth removal, a healing process begins that affects the eventual alveolar bone volume and architecture of the alveolar ridge. Satisfactory and timely healing are essential to obtain ideal functional reconstruction. Traumatic removal of a tooth, or a poor healing response, may lead to excessive bone loss delaying tooth replacement, requiring expensive and time-consuming reconstructive surgeries, or even the inability to be corrected. The Plasma Rich in Growth Factors (PRGF-Endoret) has shown its therapeutic potential effect to minimize the consequences of this aggression, promoting the regeneration of both hard and soft involved tissues.
Condition or disease
Post-Extraction Sockets Healing
Biological: Plasma Rich in Growth Factors PRGF-EndoretProcedure: Conventional closure of the lesion
Randomized Clinical Trial, Controlled With Conventional Treatment, of Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-extraction Sockets in Simple Extractions of Molars in the Mandible
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
subjects of both genders and ≥ 18 years old
Indication of a simple one molar extraction in the mandible.
Possibility of observation during the follow-up period.
Unerupted third molars or with horizontal inclination.
Severe swelling prior to surgery in the areas designated for extraction.
Suffering an alteration or a serious hematologic disease.
Be currently undergoing or have received radiotherapy, chemotherapy or immunosuppressive therapy, corticosteroids and/or anticoagulants 30 days prior to inclusion
In regular treatment with NSAIDs or other anti-inflammatory drugs.
History of chronic hepatitis or cirrhosis.
Diabetes mellitus with poor metabolic control (glycosylated hemoglobin >9%)
Patients undergoing dialysis.
Presence of malignant tumors, hemangiomas or angiomas in the extraction area.
History of ischemic heart disease in the last year.
Pregnancy or planned pregnancy during the study follow-up period.
Metabolic Bone Disease.
Patients taking bisphosphonates both orally and intravenously.
In general, any inability to participate in the study.